Evidence map›Paper›PMID 26098469›Full record

ArticleInvestigative ophthalmology & visual science2015

A Herpes Simplex Virus Type 1 Human Asymptomatic CD8+ T-Cell Epitopes-Based Vaccine Protects Against Ocular Herpes in a "Humanized" HLA Transgenic Rabbit Model.

Ruchi Srivastava, Arif A Khan, Jiawei Huang, Anthony B Nesburn, Steven L Wechsler, Lbachir BenMohamed

Open access · bronzeAbstract read
In one paragraph

Article in Investigative ophthalmology & visual science, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
3.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 31 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. The wide utility of rabbits as models of human diseases.Experimental & molecular medicine · 2018
    Review
  12. Review
  13. Article
  14. Bolstering the Number and Function of HSV-1-Specific CD8Journal of immunology (Baltimore, Md. : 1950) · 2017
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Ruchi SrivastavaLaboratory of Cellular and Molecular Immunology, Gavin Herbert Eye Institute, University of California Irvine, School of Medicine, Irvine, California, United States.
Arif A KhanLaboratory of Cellular and Molecular Immunology, Gavin Herbert Eye Institute, University of California Irvine, School of Medicine, Irvine, California, United States.
Jiawei HuangLaboratory of Cellular and Molecular Immunology, Gavin Herbert Eye Institute, University of California Irvine, School of Medicine, Irvine, California, United States.
Anthony B NesburnLaboratory of Cellular and Molecular Immunology, Gavin Herbert Eye Institute, University of California Irvine, School of Medicine, Irvine, California, United States.
Steven L WechslerLaboratory of Cellular and Molecular Immunology, Gavin Herbert Eye Institute, University of California Irvine, School of Medicine, Irvine, California, United States 2Department of Microbiology and Molecular Genetics, University of California Irvine, Schoo.
Lbachir BenMohamedLaboratory of Cellular and Molecular Immunology, Gavin Herbert Eye Institute, University of California Irvine, School of Medicine, Irvine, California, United States 4Department of Molecular Biology & Biochemistry 5Institute for Immunology, University of C.
University of California, Irvine · US

Funding

Therapeutic Ocular HSV Vaccine in HLA Transgenic RabbitsR01EY019896 · NEI · UNIVERSITY OF CALIFORNIA-IRVINE · PI BENMOHAMED, LBACHIR · 2010 to 2025
$5.1M
Ocular Mucsoal Immunity Induced by HSV-1 LipopeptidesR01EY014900 · NEI · UNIVERSITY OF CALIFORNIA-IRVINE · PI BENMOHAMED, LBACHIR · 2003 to 2014
$3.1M
Blockade of T-cell Co-Inhibitory Pathways & Immunotherapy to Prevent Ocular HerpeR01EY024618 · NEI · UNIVERSITY OF CALIFORNIA-IRVINE · PI BENMOHAMED, LBACHIR · 2014 to 2016
$1.2M
NEI NIH HHS EY019896NEI NIH HHS EY024618NEI NIH HHS EY14900NEI NIH HHS R01 EY014900NEI NIH HHS R01 EY019896NEI NIH HHS R01 EY024618
6 · The paper itself

Abstract

purposeA clinical vaccine that protects from ocular herpes simplex virus type 1 (HSV-1) infection and disease still is lacking. In the present study, preclinical vaccine trials of nine asymptomatic (ASYMP) peptides, selected from HSV-1 glycoproteins B (gB), and tegument proteins VP11/12 and VP13/14, were performed in the "humanized" HLA-transgenic rabbit (HLA-Tg rabbit) model of ocular herpes. We recently reported that these peptides are highly recognized by CD8+ T cells from "naturally" protected HSV-1-seropositive healthy ASYMP individuals (who have never had clinical herpes disease).

methodsMixtures of three ASYMP CD8+ T-cell peptides derived from either HSV-1 gB, VP11/12, or VP13/14 were delivered subcutaneously to different groups of HLA-Tg rabbits (n = 10) in incomplete Freund's adjuvant, twice at 15-day intervals. The frequency and function of HSV-1 epitope-specific CD8+ T cells induced by these peptides and their protective efficacy, in terms of survival, virus replication in the eye, and ocular herpetic disease were assessed after an ocular challenge with HSV-1 (strain McKrae).

resultsAll mixtures elicited strong and polyfunctional IFN-γ- and TNF-α-producing CD107+CD8+ cytotoxic T cells, associated with a significant reduction in death, ocular herpes infection, and disease (P < 0.015).

conclusionsThe results of this preclinical trial support the screening strategy used to select the HSV-1 ASYMP CD8+ T-cell epitopes, emphasize their valuable immunogenic and protective efficacy against ocular herpes, and provide a prototype vaccine formulation that may be highly efficacious for preventing ocular herpes in humans.

Indexed as

AnimalsAnimals, Genetically ModifiedAntigens, ViralCD8-Positive T-LymphocytesDisease Models, AnimalEpitopes, T-LymphocyteHerpes Simplex Virus VaccinesHerpesvirus 1, HumanHLA-A2 AntigenHumansImmunizationKeratitis, HerpeticRabbitsTumor Necrosis Factor-alphaAntigens, ViralEpitopes, T-LymphocyteHerpes Simplex Virus VaccinesHLA-A*02:01 antigenHLA-A2 AntigenTumor Necrosis Factor-alpha

Identifiers

PMID26098469
PMCPMC4477261
OpenAlexW2408837989

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.